SillaJen, Inc.

215600· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩2,230+3.96%

2026-08-04

Financials

Valuation Metrics

SillaJen, Inc.'s Market Cap is ₩3090B. At end of 2025 it was ₩4856B. Ranked #610 of 2,436 in KR market (top 25%), #243 of 1,649 on KOSDAQ (top 15%), #68 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.

Investment Metrics(as of 2026-08-04)

Metric	Value	Rank
Size
Market Cap	308.97B KRW	KR#610/2,436 Sec#68/234
Revenue	10.92B KRW	KR#2,273/2,436 Sec#173/234
Net Income	-24.13B KRW	KR—/2,436 Sec—/234
Total Assets	111.84B KRW	KR#1,669/2,436 Sec#136/234
Net Assets	105.29B KRW	KR#1,360/2,436 Sec#111/234
Employees	45	KR#2,067/2,436 Sec#186/234
Value
P/B	2.93x	KR#2,109/2,436 Sec#165/234
P/S	28.29x	KR#2,351/2,436 Sec#190/234
FCF Yield	-7.36%	KR—/2,436 Sec—/234
Profitability
ROE	-22.92%	KR#2,106/2,436 Sec#165/234
ROA	-21.58%	KR#2,242/2,436 Sec#180/234
Op. Margin	-239.32%	KR#2,349/2,436 Sec#192/234
Revenue Growth	146.45%	KR#97/2,436 Sec#17/234
Financial Health
Debt Ratio	106.22%	KR#369/2,436 Sec#51/234
Total Debt	750.1M KRW	KR#1,985/2,436 Sec#191/234
FCF	-22.75B KRW	KR#1,925/2,436 Sec#184/234
Cash	7.38B KRW	KR#1,832/2,436 Sec#157/234
Current Ratio	15.81x	KR#44/2,436 Sec#16/234
Performance
1Y Return	-22.84%	KR#1,353/2,436 Sec#113/234
1M Return	-3.25%	KR#1,231/2,436 Sec#122/234
From 52W High	-58.70%	KR#1,644/2,436 Sec#139/234
1Y MDD	-62.93%	KR#1,582/2,436 Sec#128/234
Trading
Volume	736,076 shares	KR#182/2,436 Sec#13/234
Foreign Own.	4.06%	KR#889/2,436 Sec#86/234
Per Share
EPS	-175 KRW	KR—/2,436 Sec—/234
BPS	762 KRW	KR#2,341/2,436 Sec#216/234

Company Info

CEO 김재경

Employees 45

Founded 2006

HQ 서울특별시 중구, KR

Website www.sillajen.com

동사는 2006년 항암 신약개발을 위해 설립된 바이오 벤처기업이고, 2016년 코스닥시장에 상장함. 암세포 사멸 및 면역기능 활성화를 목표로 유전자 재조합 항암바이러스 기반 치료제를 개발하고, 2025년 (주)우성제약 합병으로 제약사업을 확장함. 항암바이러스 단독요법과 면역관문억제제 병용요법, 유사분열 체크포인트 억제제 연구를 하고, 제약사업부문에서 다양한 신약 개발을 추진하고 있음. 신라젠는 2006년에 설립되었으며 서울특별시 중구에 본사를 두고 있습니다.